David Shaw’s Mustang Bio MBIO Stock Holding History

David Shaw’s Portfolio MBIO Stock Details MBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-584	Closed	-$443K	–	5584
2022 Q1	$443K	Buy	584 +175	+43%	+$144K	﹤0.01%	4446
2021 Q4	$509K	Buy	409 +256	+167%	+$413K	﹤0.01%	4390
2021 Q3	$308K	Buy	153 +65	+74%	+$140K	﹤0.01%	4337
2021 Q2	$220K	Buy	+88	New	+$216K	﹤0.01%	4413

Other funds holding MBIO

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

David Shaw's MBIO Position: Q2 2022 in Review

David Shaw sold out of Mustang Bio (MBIO) in Q2 2022, closing a stake of 584 shares — an estimated $443K sold.

David Shaw first reported a position in MBIO in Q2 2021 and held it in 4 quarters. The position peaked at $509K in Q4 2021. 71 funds tracked by Wall St. Rank hold MBIO as of Q2 2022.

David Shaw reported no remaining Mustang Bio position as of Q2 2022 after selling out during the quarter.
David Shaw sold 584 Mustang Bio shares in Q2 2022, an estimated $443K.
David Shaw first reported a position in Mustang Bio in Q2 2021 and held it in 4 quarters.
David Shaw's Mustang Bio position peaked at $509K in Q4 2021.
71 funds tracked by Wall St. Rank held Mustang Bio as of Q2 2022.

Based on D.E. Shaw & Co's 13F filing for Q2 2022, filed 15 Aug 2022.